StreetAlpha
13F holdings · Q3 2026

Affinity Asset Advisors

New York, NY · files as Affinity Asset Advisors, LLC
Know the moment Affinity Asset Advisors filesYou follow Affinity Asset Advisors An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 1773195

Affinity Asset Advisors reported 106 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are ROIV (6.8%), SYRE (6.6%) and ERAS (4.8%). Compared with Q2 2026, the fund opened new positions in VOGX, ARVN and IBRX, added to ERAS, TRAX and XENE, trimmed ROIV, INSM and RVMD and sold out of COGT, QURE and ASND.

Latest filing: what Affinity Asset Advisors did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
25 new27 added26 trimmed20 sold outBought about $304M · sold about $426M
New 25
See all 25 →
Added 27
See all 27 →
Trimmed 26
See all 26 →
Sold out 20
  • Apogee Therapeutic$131M
  • Nuvalent Inc$34M
  • Forte Biosciences $24.3M
  • COGT$17.4M
  • Teva Pharmaceutica$12.7M
See all 20 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.7B−14.6% vs last quarter · $2.4B including options
Stocks held10625 new · 20 sold out
Top 5 weight26.6%spread out
Turnover43%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
ROIV
Roivant Sciences Ltd
$117M6.8%3.2M−550K (−15%)7 of 8
2
SYRE
Spyre Therapeutics Inc
$114M6.6%1.3MNo change8 of 8
3
ERAS
Erasca Inc
$82M4.8%5.6M+341K (+6%)8 of 8
4
TRAX
First Tracks Biotherapeutics
$73.7M4.3%2.1M+48K (+2%)2 of 8
5
XENE
Xenon Pharmaceuticals Inc
$70.7M4.1%1.9M+305K (+19%)8 of 8
6
INSM
Insmed Inc
$64.4M3.7%564K−86K (−13%)8 of 8
7
ALKS
Alkermes PLC
$63.4M3.7%1.6M+440K (+39%)8 of 8
8
ORKA
Oruka Therapeutics Inc
$50M2.9%600K+10K (+2%)8 of 8
9
AVTX
Avalo Therapeutics Inc
$49.7M2.9%3.2M+345K (+12%)8 of 8
10
CYTK
Cytokinetics Inc
$49.4M2.9%750K+200K (+36%)5 of 8
🔒 96 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
APOGEE THERAPEUTICS INC
$131M987K
NUVALENT INC
$34M275K
FORTE BIOSCIENCES INC
$24.3M1.1M
COGT
Cogent Biosciences Inc
$17.4M450K
TEVA PHARMACEUTICAL INDS LTD
$12.7M374K

🔒 Free account: see all 20.

Options

valued at the underlying shares
StockTypeValueSharesChange
IWM
Ishares TR
Put$278M1M+1,000,000
XBI
Spdr Series Trust
Put$94.6M600K+600,000
MRNA
Moderna Inc
Put$62.6M325K−175,000
ARKG
ARK Genomic Revolution
Put$54.2M1M+1,000,000
ARKG
ARK Genomic Revolution
Call$51.5M950K+200,000

🔒 Free account: see all 12.

Reported value

last 8 quarters
$592MQ4 '24
$606MQ1 '25
$651MQ2 '25
$1BQ3 '25
$1.4BQ4 '25
$1.7BQ1 '26
$2BQ2 '26
$1.7BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Affinity Asset Advisors 13F FAQ

What does Affinity Asset Advisors own?

Affinity Asset Advisors reported 106 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are ROIV (6.8%), SYRE (6.6%) and ERAS (4.8%). The table above lists every position in the filing (the top 10 without an account).

What did Affinity Asset Advisors buy and sell in Q3 2026?

Compared with Q2 2026: 25 new positions, 27 added to, 26 trimmed and 20 sold out. New positions include VOGX, ARVN and IBRX. It sold all of COGT, QURE and ASND.

When will Affinity Asset Advisors file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Affinity Asset Advisors's portfolio worth?

The Q3 2026 filing reports $1.7B in US stocks ($2.4B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.